AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30363395 — intervention group
Group type: EXPERIMENTAL
Intervention: HD gene expansion carriers (HDGECs; CAG expansion ≥36)
Number of subjects: 1534
Study 30363395 — intervention group
Group type: EXPERIMENTAL
Intervention: Premanifest HD
Number of subjects: 1534
Study 30363395 — intervention group
Group type: EXPERIMENTAL
Intervention: Manifest HD
Number of subjects: 1534
Study 30363395 — intervention group
Group type: COMPARATOR
Intervention: Controls (genotype-negative first-degree relatives and family controls)
Number of subjects: 1534
Study 30363894 — intervention group
Group type: EXPERIMENTAL
Intervention: l-tyrosine 1,000 mg (500 mg 2× daily) for 7 days
Number of subjects: 36
Study 30363894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30363900 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemical Skin Conductance (ESC) assessment
Number of subjects: 36
Study 30363954 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of aerobic and/or resistance training
Number of subjects: 202
Study 30363954 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 202
Study 30364428 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01 (40 mg/kg)
Number of subjects: 0
Study 30364428 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study 30364428 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01
Number of subjects: 0
Study 30364428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30364565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (CRT)
Number of subjects: 52
Study 30364565 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-peptides of collagen I and III, collagen I C-terminal telopeptides (CTx), matrix metalloproteinases (MMP-2 and MMP-9), and a panel of miRNAs (miRNA-21, miRNA-30d, miRNA-122, miRNA-133a, miRNA-210 and miRNA-486)
Number of subjects: 52
Study 30364785 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated phone reminders (up to 6 reminders)
Number of subjects: 427
Study 30364785 — intervention group
Group type: COMPARATOR
Intervention: Automated plus live phone reminders (up to 6 reminders total)
Number of subjects: 427
Study 30364785 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated phone reminders (up to 6 reminders) among Spanish-preferring patients (n=106)
Number of subjects: 427
Study 30364785 — intervention group
Group type: COMPARATOR
Intervention: Automated plus live phone reminders among Spanish-preferring patients (n=106)
Number of subjects: 427
Study 30364785 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated phone reminders (up to 6 reminders) among English-preferring patients (n=279)
Number of subjects: 427
Study 30364785 — intervention group
Group type: COMPARATOR
Intervention: Automated plus live phone reminders among English-preferring patients (n=279)
Number of subjects: 427
Study 30365164 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI surveillance
Number of subjects: 71
Study 30365164 — intervention group
Group type: COMPARATOR
Intervention: US surveillance
Number of subjects: 71
Study 30365251 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD group
Number of subjects: 116
Study 30365251 — intervention group
Group type: COMPARATOR
Intervention: TD group
Number of subjects: 116
Study 30365452 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC + DRV/r (once daily; 4 pills/day)
Number of subjects: 774
Study 30365452 — intervention group
Group type: COMPARATOR
Intervention: RAL + DRV/r (twice daily; 5 pills/day)
Number of subjects: 774
Study 30365452 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence ≥95% over the last 4 days
Number of subjects: 774
Study 30365452 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with baseline CD4 <200 cells/mm and HIV-1 RNA ≥100,000 copies per milliliter
Number of subjects: 774
Study 30366567 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% testosterone gel daily for 12 months
Number of subjects: 390
Study 30366567 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel daily for 12 months
Number of subjects: 390
Study 30366581 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening test panel (clinical evaluation, daytime arterial blood gas (ABG), nocturnal pulse oximetry (SpO2))
Number of subjects: 67
Study 30366581 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening test panel
Number of subjects: 67
Study 30366585 — intervention group
Group type: EXPERIMENTAL
Intervention: Breezhaler inhaler
Number of subjects: 0
Study 30366585 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30366774 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased daily portion of fruits and vegetables
Number of subjects: 48
Study 30366774 — intervention group
Group type: COMPARATOR
Intervention: High screen time, high saturated fat, high sugar-sweetened beverages, low protein intake
Number of subjects: 48
Study 30367117 — intervention group
Group type: EXPERIMENTAL
Intervention: ETS+ tumors
Number of subjects: 10608
Study 30367117 — intervention group
Group type: EXPERIMENTAL
Intervention: ETS- tumors
Number of subjects: 10608
Study 30367117 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-regulated gene expression
Number of subjects: 10608
Study 30367117 — intervention group
Group type: EXPERIMENTAL
Intervention: GSEA
Number of subjects: 10608
Study 30367117 — intervention group
Group type: EXPERIMENTAL
Intervention: AR ChIP-seq data
Number of subjects: 10608
Study 30367117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysregulation of ETS-dependent AR-target genes
Number of subjects: 10608
Study 30367670 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (pre-existing co-morbidity)
Number of subjects: 4107
Study 30367875 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeWalker (LW)
Number of subjects: 30
Study 30367875 — intervention group
Group type: COMPARATOR
Intervention: Standard Rollator (SR)
Number of subjects: 30
Study 30367875 — intervention group
Group type: COMPARATOR
Intervention: Participants' Predicate Device (PD)
Number of subjects: 30
Study 30368038 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (HC)
Number of subjects: 3649
Study 30368038 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide (ANA)
Number of subjects: 3649
Study 30368038 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HC and ANA
Number of subjects: 3649
Study 30368038 — intervention group
Group type: COMPARATOR
Intervention: HC
Number of subjects: 3649
Study 30368548 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (4/0.5 g, tid) administered over 0.5 h
Number of subjects: 20
Study 30368548 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 ICU patients)
Number of subjects: 20
Study 30368788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution (standardized formulation)
Number of subjects: 0
Study 30368788 — intervention group
Group type: COMPARATOR
Intervention: Various investigational compounds (anakinra, cannabidiol, cannabidivarin, fenfluramine, ganaxolone, medium-chain fatty acids, padsevonil, valnoctamide, sec-butylpropylacetamide)
Number of subjects: 0
Study 30368871 — intervention group
Group type: EXPERIMENTAL
Intervention: Columbia-Suicide Severity Rating Scale (C-SSRS)
Number of subjects: 237
Study 30368871 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline intensity subscale scores
Number of subjects: 237
Study 30368871 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline severity subscale scores
Number of subjects: 237
Study 30368871 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of ideation cutoff scores
Number of subjects: 237
Study 30368871 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior behavior criterion
Number of subjects: 237
Study 30369044 — intervention group
Group type: EXPERIMENTAL
Intervention: HPS6 genetic analysis and platelet electron microscopy
Number of subjects: 1
Study 30369044 — intervention group
Group type: COMPARATOR
Intervention: Control cells
Number of subjects: 1
Study 30369290 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 0
Study 30369290 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30369317 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 30370457 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation for <100 cc prostates
Number of subjects: 101
Study 30370457 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation for >100 cc prostates
Number of subjects: 101
Study 30370468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab monotherapy (8 mg/kg)
Number of subjects: 200
Study 30370468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab combined with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)
Number of subjects: 200
Study 30370468 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab monotherapy
Number of subjects: 200
Study 30370468 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab combined with csDMARDs
Number of subjects: 200
Study 30370691 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite estimand approach
Number of subjects: 0
Study 30370691 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment policy estimand
Number of subjects: 0
Study 30371223 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 737
Study 30371223 — intervention group
Group type: COMPARATOR
Intervention: Not taking SSRIs (Control)
Number of subjects: 737
Study 30371223 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban with SSRIs
Number of subjects: 737
Study 30371223 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin with SSRIs
Number of subjects: 737
Study 30371223 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 737
Study 30371285 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGGIC risk score (mean ± SD of 18 ± 7)
Number of subjects: 407
Study 30371285 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGGIC risk score
Number of subjects: 407
Study 30371285 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGGIC risk score with B-type natriuretic peptide
Number of subjects: 407
Study 30371301 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once-weekly
Number of subjects: 14752
Study 30371728 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted ACC/AHA BPM procedure
Number of subjects: 805
Study 30371728 — intervention group
Group type: COMPARATOR
Intervention: CHEP BPM procedure
Number of subjects: 805
Study 30371784 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional cavopulmonary connection
Number of subjects: 39
Study 30371784 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cavopulmonary connection
Number of subjects: 39
Study 30371784 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 39
Study 30371784 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 39
Study 30372653 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-rated working alliance
Number of subjects: 73
Study 30372653 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-rated alliance
Number of subjects: 73
Study 30373560 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved cookstoves offered at randomly varying prices to peers of households that had previously received stoves for free.
Number of subjects: 0
Study 30373560 — intervention group
Group type: COMPARATOR
Intervention: Improved cookstoves offered at randomly varying prices to non-peers of households that had previously received stoves for free.
Number of subjects: 0
Study 30373600 — intervention group
Group type: EXPERIMENTAL
Intervention: microRNA array
Number of subjects: 40
Study 30373600 — intervention group
Group type: EXPERIMENTAL
Intervention: TaqMan Real-time PCR
Number of subjects: 40
Study 30373638 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE)
Number of subjects: 20
Study 30373653 — intervention group
Group type: EXPERIMENTAL
Intervention: APPROVE (automated electronic health record-based model)
Number of subjects: 68875
Study 30373653 — intervention group
Group type: EXPERIMENTAL
Intervention: APPROVE (threshold > 0.25)
Number of subjects: 68875
Study 30373653 — intervention group
Group type: COMPARATOR
Intervention: MEWS (Modified Early Warning Score)
Number of subjects: 68875
Study 30373653 — intervention group
Group type: COMPARATOR
Intervention: NEWS (National Early Warning Score)
Number of subjects: 68875
Study 30373653 — intervention group
Group type: COMPARATOR
Intervention: MEWS and NEWS (threshold > 4)
Number of subjects: 68875
Study 30373671 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood asthma (self-reported, diagnosed by a medical professional, onset < 16 years)
Number of subjects: 10199
Study 30373671 — intervention group
Group type: COMPARATOR
Intervention: No history of asthma
Number of subjects: 10199
Study 30373671 — intervention group
Group type: EXPERIMENTAL
Intervention: GWAS in NHW and AA populations
Number of subjects: 10199
Study 30373683 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) severity
Number of subjects: 98
Study 30373683 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure control with medications
Number of subjects: 98
Study 30373731 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 20 minutes, 15 sessions)
Number of subjects: 94
Study 30373731 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (2 mA for 20 minutes, 15 sessions)
Number of subjects: 94
Study 30373731 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 94
Study 30373731 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 94
Study 30373783 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of severe ischaemic stroke
Number of subjects: 2500
Study 30373783 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up management of severe ischaemic stroke
Number of subjects: 2500
Study 30373800 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) with limited sampling strategies (LSSs)
Number of subjects: 0
Study 30374460 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Number of subjects: 34
Study 30374460 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower pretreatment plasma HGF level
Number of subjects: 34
Study 30374686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg, every 2 weeks) with temsirolimus (25 mg weekly)
Number of subjects: 39
Study 30375693 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral therapy
Number of subjects: 191
Study 30376863 — intervention group
Group type: EXPERIMENTAL
Intervention: GTP group
Number of subjects: 20
Study 30376863 — intervention group
Group type: EXPERIMENTAL
Intervention: TTP group
Number of subjects: 20
Study 30376863 — intervention group
Group type: COMPARATOR
Intervention: Control muscle (m. vastus lateralis)
Number of subjects: 20
Study 30376863 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (TTP, GTP, Control)
Number of subjects: 20
Study 30377142 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone app for self-management of T1DM
Number of subjects: 154000
Study 30377191 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Carnitine Challenge Test (OCCT)
Number of subjects: 57
Study 30377436 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PCOS
Number of subjects: 86
Study 30377436 — intervention group
Group type: COMPARATOR
Intervention: Women with T2DM
Number of subjects: 86
Study 30377436 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PCOS (inflexible)
Number of subjects: 86
Study 30377537 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga, implemented via twice weekly 60-min group-based classes for 12 weeks.
Number of subjects: 0
Study 30377537 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no specific intervention details provided).
Number of subjects: 0
Study 30377539 — intervention group
Group type: EXPERIMENTAL
Intervention: High neighborhood social disorganization
Number of subjects: 424
Study 30377539 — intervention group
Group type: EXPERIMENTAL
Intervention: High neighborhood economic disadvantage
Number of subjects: 424
Study 30377539 — intervention group
Group type: COMPARATOR
Intervention: Controlling for individual level variables
Number of subjects: 424
Study 30377677 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 fatty acid status testing
Number of subjects: 100
Study 30377677 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish intake
Number of subjects: 100
Study 30377677 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 supplement use
Number of subjects: 100
Study 30377677 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived ω-3 status
Number of subjects: 100
Study 30377981 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of Care measure delivered through Qualtrics to HIV care providers
Number of subjects: 75
Study 30377981 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of Care measure
Number of subjects: 75
Study 30377991 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab (specific dosage and duration not mentioned)
Number of subjects: 0
Study 30378520 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe food insecurity among pregnant women
Number of subjects: 1230
Study 30378520 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate food insecurity among pregnant women
Number of subjects: 1230
Study 30378520 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild, moderate, and severe food insecurity among lactating women
Number of subjects: 1230
Study 30378520 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and severe food insecurity among lactating women
Number of subjects: 1230
Study 30378520 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity levels among lactating women
Number of subjects: 1230
Study 30380032 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired endogenous fibrinolysis (baseline lysis time (LT) ≥2500 s)
Number of subjects: 496
Study 30380032 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired endogenous fibrinolysis
Number of subjects: 496
Study 30380032 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous ST-segment resolution pre-PPCI
Number of subjects: 496
Study 30380032 — intervention group
Group type: COMPARATOR
Intervention: Standard of care STEMI treatment including DAPT
Number of subjects: 496
Study 30380060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg q12h by 1 h intravenous infusion
Number of subjects: 951
Study 30380060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg q8h by 2 h intravenous infusion
Number of subjects: 951
Study 30380386 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu5F9-G4 (5F9) antibody with rituximab
Number of subjects: 22
Study 30381078 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-707
Number of subjects: 2
Study 30381078 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 2
Study 30381282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements (protein isolate powder, immunomodulation solution, carbohydrate loading)
Number of subjects: 165
Study 30381282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements
Number of subjects: 165
Study 30382017 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-fluorodeoxyglucose (PET)
Number of subjects: 82
Study 30382017 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C-raclopride (PET)
Number of subjects: 82
Study 30382017 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C-FLB 457 (PET)
Number of subjects: 82
Study 30382017 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric tests
Number of subjects: 82
Study 30382017 — intervention group
Group type: EXPERIMENTAL
Intervention: D2-receptor availability assessment
Number of subjects: 82
Study 30382161 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 0
Study 30382850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic implants (PURE Ceramic Implant, Institut Straumann AG, Basel, Switzerland) with a diameter of 4.1 mm
Number of subjects: 44
Study 30382910 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental insurance
Number of subjects: 100
Study 30382910 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting a dental insurance barrier to care
Number of subjects: 100
Study 30382910 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher motivation to visit the dentist
Number of subjects: 100
Study 30382910 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy to visit the dentist
Number of subjects: 100
Study 30382910 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a disability
Number of subjects: 100
Study 30382910 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education level
Number of subjects: 100
Study 30382910 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived gum disease
Number of subjects: 100
Study 30382910 — intervention group
Group type: COMPARATOR
Intervention: Being married
Number of subjects: 100
Study 30382910 — intervention group
Group type: COMPARATOR
Intervention: Not having a last dental cleaning within the past year
Number of subjects: 100
Study 30382912 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Profile Survey (CPS)
Number of subjects: 84
Study 30382942 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir+sofosbuvir+ribavirin for 24 weeks
Number of subjects: 78
Study 30383134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 40 mg
Number of subjects: 38
Study 30383134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 80 mg
Number of subjects: 38
Study 30383134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30383139 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 65093
Study 30383139 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 65093
Study 30383139 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable gastric banding (AGB)
Number of subjects: 65093
Study 30383139 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB) vs Sleeve gastrectomy (SG)
Number of subjects: 65093